Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SZSE:002940), Hunan Chuntou Industrial Development Co., Ltd., Changde Yuanli Industrial Investment Holding Co., Ltd., Jinshi Jiashan Industrial Development Investment Co., Ltd., Lijiang Shengchuang Pharmaceutical Co., Ltd., Mr. Zhu Guoliang and Ms. He Lizhao agreed to acquire 74.8057% stake in Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. from Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) for approximately CNY 820 million on January 28, 2022. Guangdong Shall pay 20% deposit within 10 days from the day signing the contract. At the same time, 80% of the equity transfer payment should be paid to the joint management account. Financials reported as at September 30, 2021, revenue of CNY 546 million, total assets of CNY 1598 million, net assets of CNY 598 million and net income of CNY 18.6 million. Approval obtained in the tenth meeting of the third board of directors of the company on January 28, 2022.

Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SZSE:002940), Hunan Chuntou Industrial Development Co., Ltd., Changde Yuanli Industrial Investment Holding Co., Ltd., Jinshi Jiashan Industrial Development Investment Co., Ltd., Lijiang Shengchuang Pharmaceutical Co., Ltd., Mr. Zhu Guoliang and Ms. He Lizhao completed the acquisition of 74.8057% stake in Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. from Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) on April 26, 2022.